At GoBroad Healthcare Group, we understand that a diagnosis of solid tumors—whether in the lungs, gastrointestinal tract, breast, or other organs—demands precision, innovation, and compassion. As a network of specialized hospitals across Beijing, Shanghai, and Guangzhou, we’ve dedicated ourselves to redefining treatment for solid tumors through a blend of multidisciplinary expertise, cutting-edge research, and individualized care. Our Academic Research Organization (ARO) model ensures that every breakthrough in oncology translates into tangible solutions, offering hope to patients navigating complex or recurrent cancers.

Multidisciplinary Collaboration: The Core of Effective Treatment for Solid Tumors

Solid tumors require more than a single specialist’s perspective—they demand a united front of experts. At GoBroad, our Multidisciplinary Care (MDC) teams bring together surgeons, oncologists, radiologists, and pathologists to design personalized strategies. For instance, a patient with hepatobiliary tumors might undergo minimally invasive laparoscopic surgery guided by real-time imaging, followed by targeted therapy informed by genetic profiling. Similarly, those with bone and soft tissue sarcomas benefit from protocols that combine precise radiation techniques like TOMO therapy with immunotherapy or clinical trial medications. This collaborative model extends to complex cases, such as metastatic gastrointestinal tumors, where interventional radiologists and medical oncologists work in tandem to deploy arterial infusion chemotherapy or chemoembolization. By integrating diverse perspectives, we ensure treatment for solid tumors addresses not just the disease, but the unique needs of each patient.

Bridging Innovation and Clinical Practice in Treatment for Solid Tumors

Our status as an ARO enables us to fast-track emerging therapies from lab to bedside. Through partnerships with institutions like China Pharmaceutical University, we pioneer clinical trials exploring novel combinations—such as immunotherapy paired with cellular therapies—for refractory solid tumors. Patients like those with KRAS-mutated lung cancers have accessed groundbreaking drugs like Furazercib within days of regulatory approval, often alongside conventional treatments. Our Phase I trial wards and central laboratories play a pivotal role, conducting pharmacogenetic testing to identify biomarkers that predict drug efficacy or toxicity. For example, a breast cancer patient’s treatment plan might evolve from standard chemotherapy to a tailored regimen of molecular-targeted drugs, guided by real-time genetic sequencing. This agility ensures treatment for solid tumors at GoBroad remains at the forefront of oncology, offering options even when traditional methods stall.

Specialized Protocols for Every Tumor Type

The diversity of solid tumors necessitates equally diverse strategies. For gastrointestinal cancers, our approach spans early screening via advanced endoscopy to minimally invasive resections and post-operative immunotherapy. Pancreatic and hepatobiliary tumors, known for their complexity, are managed with precision surgery in hundred-level laminar flow operating rooms, combined with adjuvant therapies like tumor ablation or peptide receptor radionuclide therapy. Breast cancer patients receive stage-specific care, from lumpectomies with oncoplastic techniques to advanced HER2-targeted regimens. Meanwhile, our sarcoma specialists leverage next-generation sequencing to differentiate subtypes, enabling therapies as specific as CDK4/6 inhibitors for liposarcomas. Each protocol underscores our belief that effective treatment for solid tumors must be as unique as the biology it targets.

Conclusion

At GoBroad Healthcare Group, treatment for solid tumors is more than a medical protocol—it’s a commitment to innovation, collaboration, and above all, the patient. Whether through MDC-designed plans, access to global-first therapies, or tumor-specific expertise, we strive to turn daunting diagnoses into journeys of resilience.